MK-2214

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Alzheimer DiseaseAlzheimer’s DiseaseEarly Alzheimer's Disease

Phase 1

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

CompletedNCT05466422

Merck Sharp & Dohme LLCAlzheimer Disease

Start: 2022-09-20End: 2025-07-03Updated: 2025-08-27

Phase 2

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

RecruitingNCT07033494

Merck Sharp & Dohme LLCEarly Alzheimer's Disease

Start: 2025-07-16End: 2029-04-30Target: 340Updated: 2026-04-03

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease

RecruitingCTIS2024-519190-19-00

Merck Sharp & Dohme LLCAlzheimer’s Disease

Start: 2025-10-03Target: 58Updated: 2025-11-07